GSEA revealed that gene sets associated with the NASH phenotype were enriched in the LCN2-high subgroup (Fig. 7b, c), indicating that hepatic LCN2 expression was positively correlated with clinically defined NASH in humans. Here, LCN2 is linked to metabolic dysfunction-associated steatohepatitis.